Free Trial
NASDAQ:ERAS

Erasca (ERAS) Stock Price, News & Analysis

Erasca logo
$1.21 -0.05 (-3.97%)
Closing price 04:00 PM Eastern
Extended Trading
$1.22 +0.01 (+0.41%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Erasca Stock (NASDAQ:ERAS)

Key Stats

Today's Range
$1.17
$1.27
50-Day Range
$1.21
$1.95
52-Week Range
$1.04
$3.45
Volume
1.55 million shs
Average Volume
1.78 million shs
Market Capitalization
$342.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.83
Consensus Rating
Buy

Company Overview

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Remove Ads

Erasca Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

ERAS MarketRank™: 

Erasca scored higher than 73% of companies evaluated by MarketBeat, and ranked 221st out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Erasca has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Erasca has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Erasca's stock forecast and price target.
  • Earnings Growth

    Earnings for Erasca are expected to grow in the coming year, from ($0.73) to ($0.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Erasca is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Erasca is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Erasca has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Erasca's valuation and earnings.
  • Percentage of Shares Shorted

    20.21% of the float of Erasca has been sold short.
  • Short Interest Ratio / Days to Cover

    Erasca has a short interest ratio ("days to cover") of 22.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Erasca has recently decreased by 2.24%, indicating that investor sentiment is improving.
  • Dividend Yield

    Erasca does not currently pay a dividend.

  • Dividend Growth

    Erasca does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.21% of the float of Erasca has been sold short.
  • Short Interest Ratio / Days to Cover

    Erasca has a short interest ratio ("days to cover") of 22.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Erasca has recently decreased by 2.24%, indicating that investor sentiment is improving.
  • News Sentiment

    Erasca has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Erasca this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for ERAS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Erasca to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Erasca insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.50% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Erasca's insider trading history.
Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Stock News Headlines

Erasca (ERAS) Gets a Buy from J.P. Morgan
Bank of America Securities Sticks to Its Buy Rating for Erasca (ERAS)
Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
Raymond James Begins Coverage on Erasca (NASDAQ:ERAS)
Erasca reports Q4 EPS (11c), consensus (13c)
See More Headlines

ERAS Stock Analysis - Frequently Asked Questions

Erasca's stock was trading at $2.51 at the beginning of 2025. Since then, ERAS shares have decreased by 51.8% and is now trading at $1.21.
View the best growth stocks for 2025 here
.

Erasca, Inc. (NASDAQ:ERAS) issued its quarterly earnings data on Thursday, March, 20th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01.

Erasca (ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Erasca investors own include Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
3/20/2025
Today
4/03/2025
Next Earnings (Estimated)
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ERAS
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.83
High Stock Price Target
$6.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+299.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-125,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.10 per share
Price / Book
0.58

Miscellaneous

Free Float
221,941,000
Market Cap
$342.75 million
Optionable
Optionable
Beta
1.22
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ERAS) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners